



William BAINS

After a first degree at Oxford, PhD at Warwick and Postdoc at Stanford, California, William held a lectureship at University of Bath, researching *inter alia* genomics and bioinformatics technologies. In 1988 he joined PA Consulting Group, and in October 1996 he joined Merlin Ventures, a specialist bioscience investment group where he wrote the business plans for Ark Therapeutics among others. In 1999 William founded his first start-up biotech company, Amedis Pharmaceuticals Ltd, which he took from concept through three funding rounds to an established company with a strong management team, two technology platforms, a major Pharmaceutical collaboration and product development programmes. Since leaving Amedis William has been a founder of a further four biotech companies, is a Board member of several others and a founding trustee of the Biogerontology Research Foundation. He also runs a consulting company, Rufus Scientific, providing advice on identifying and exploiting genuinely breakthrough science and technology, and teaches entrepreneurship and company creation Cambridge University.

William's expertise has been recognised with Toshiba Year of Invention prize in 1992, election to Human Genome Organisation in 1994, and appointment as a visiting Professor at Imperial College, London in 1999. He is author of numerous papers and patents and four books, and is editor-in-chief of *Bioscience Hypotheses*, an Elsevier journal that publishes innovative new ideas, theories and speculations in the life sciences and technologies.